ReviewEndocrine connections2018
Exogenous insulin antibody syndrome (EIAS): a clinical syndrome associated with insulin antibodies induced by exogenous insulin in diabetic patients.
Review in Endocrine connections, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 78 citations in OpenAlex.
- Article
- How to manage patients with diabetes suffering from unstable blood glucose control due to insulin antibodies.Endocrine · 2026Article
- Clinical characteristics and individualized treatment strategies for children with type 1 diabetes and exogenous insulin antibody syndrome: a retrospective case series and literature review.Frontiers in endocrinology · 2026Review
- Clinical Characteristics and Risk Factors of Exogenous Insulin Antibody Syndrome in Patients with Diabetes: A Retrospective Cross-Sectional Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Exogenous Insulin Antibody Syndrome: An Overlooked Cause of Severe Hypoglycemia and Insulin Resistance in a Patient With Type 2 Diabetes Treated With Insulin.Journal of general and family medicine · 2026Article
- Case Report: Rapid loss of endogenous insulin secretion and reversible subcutaneous insulin resistance following exogenous insulin exposure in a patient initially diagnosed with type 2 diabetes.Frontiers in endocrinology · 2026Article
- Exogenous Insulin Antibody Syndrome and Subsequent Severe Subcutaneous Insulin Resistance Complicating Type 1 Diabetes.JCEM case reports · 2026Article
- Diagnostic utility of the insulin-to-C-peptide molar ratio in differentiating insulin autoimmune syndrome and exogenous insulin antibody syndrome from insulinoma.Frontiers in endocrinology · 2026Article
- Impact of concomitant use of antiplatelet agents on the production of anti-insulin antibodies in patients with type 2 diabetes treated with insulin analogues.Diabetology international · 2025Article
- Exogenous Insulin Antibody Syndrome: A Rare Cause of Extreme Insulin Resistance Treated With High-dose Corticosteroids.JCEM case reports · 2025Article
- Exogenous insulin-associated autoimmunity and the emergence of double diabetes in type 2 diabetes.World journal of diabetes · 2025Article
- Successful treatment with rituximab of a type 2 diabetes patient with antibody-mediated insulin resistance syndrome: A case report.Medicine · 2025Article
- Insulin Autoimmune Syndrome: A Chinese Expert Consensus Statement.Aging medicine (Milton (N.S.W)) · 2025Article
- Exogenous insulin autoimmune syndrome: a case report and literature review.Frontiers in endocrinology · 2025Review
- Case Report: Exogenous insulin antibody syndrome complicated with chronic renal failure and long-term history of type 2 diabetes: report of two cases.Frontiers in endocrinology · 2025Article
- Article
- Article
- Development and Characterization of Guinea Pig Anti-Insulin Polyclonal Antibody.Applied biochemistry and biotechnology · 2024Article
- Exogenous Insulin Antibody Syndrome (EIAS) Presenting in an Elderly, Long-Term Patient with Type 1 Diabetes Mellitus that Resolved with Low-Cost Outpatient Therapy with Mycophenolate Mofetil and Regular Insulin by Pump.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Article
- Effect of the sodium-glucose cotransporter-2 inhibitor, DWP16001, as an add-on therapy to insulin for diabetic dogs: A pilot study.Veterinary medicine and science · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insulin has been used for diabetes therapy and has achieved significant therapeutic effect. In recent years, the use of purified and recombinant human insulin preparations has markedly reduced, but not completely suppressed, the incidence of insulin antibodies (IAs). IAs induced by exogenous insulin in diabetic patients is associated with clinical events, which is named exogenous insulin antibody syndrome (EIAS). The present review is based on our research and summarizes the characterization of IAs, the factors affecting IA development, the clinical significance of IAs and the treatments for EIAS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.